CCIA
COGT icon

Campbell & Co Investment Adviser’s Cogent Biosciences COGT Stock Holding History

Campbell & Co Investment Adviser’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,940
Closed -$673K – 1127
2025
Q4 		$673K Sell
18,940
-42,694
-69% -$1.2M 0.03% 717
2025
Q3 		$885K Buy
+61,634
New +$730K 0.07% 466

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Campbell & Co Investment Adviser's COGT Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of Cogent Biosciences (COGT) in Q1 2026, closing a stake of 18,940 shares — an estimated $673K sold.

Campbell & Co Investment Adviser first reported a position in COGT in Q3 2025 and held it in 2 quarters. The position peaked at $885K in Q3 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Campbell & Co Investment Adviser reported no remaining Cogent Biosciences position as of Q1 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 18,940 Cogent Biosciences shares in Q1 2026, an estimated $673K.
  • Campbell & Co Investment Adviser first reported a position in Cogent Biosciences in Q3 2025 and held it in 2 quarters.
  • Campbell & Co Investment Adviser's Cogent Biosciences position peaked at $885K in Q3 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.